"Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.," Leonard Zahr wrote in a feature article on Xagenic's product development progress for BioTuesdays on April 19, 2016.
Xagenic was founded by University of Toronto Professor Shana Kelley in partnership with MaRS Innovation and U of T's Innovations & Partnerships Office in 2010. The company ...
Results for results in docetaxel-resistant prostate cancer models presented at the American Association for Cancer Research (AACR) Conference
TORONTO and SAN DIEGO (April 18, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, and the Ontario Institute for Cancer Research (OICR), today announced positive results from a preclinical study of their CBZed-Nano™ (cabazitaxel cellulose nanoparticle) product in docetaxel-resistant prostate cancer mouse models. Preliminary results also showed that the nanoparticles accumulate in intracranial brain ...
Joel Liederman, vice-president of Physical Sciences, appeared on CanadaAM April 5, 2016 to talk about how to make a product. The interview is part of CanadaAM's "What's Next" segment on technology and entrepreneurship.
He and host Beverly Thomson discussed the process for moving from a napkin to a prototype to a market-ready product, including market testing, prototyping, soliciting more customer feedback, and eventually product launch.
"Marketing a product is a lot easier now than it used to be," said Liederman. "In the ...
TORONTO (March 17, 2016) — QD Solar, a Canadian technology company created by the University of Toronto (U of T) and MaRS Innovation, has received $2.55 million from the Sustainable Development Technology Canada (SDTC).
QD Solar’s funding — announced March 4, 2016 in Edmonton, Alberta by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development — will galvanize a larger $8.7 million project to revolutionize conventional solar panels that waste a large portion of the available energy in sunlight because ...
Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017
HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation.
This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today.
VICE featured XOR's life-saving lung transplant technology ...
BlueDot, a Canadian company that helps decision-makers prepare for and response to infectious disease outbreaks, was profiled in the Toronto Star for their work in tracking the Zika virus.
The company, founded by Dr. Kamran Khan, was spun-off from St. Michael's Hospital in partnership with MaRS Innovation. The company raised a Series A with Horzions Ventures in 2015.
Here's an excerpt from Kate Allen's article:
Wayne Gretzky may be an unlikely inspiration for an infectious disease researcher. Yet here Dr. Kamran Khan is, on ...
Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)
TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto.
SCX-001 is the ...
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...